Yongtao Li

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects

John D. Davis, Meng Li, M. Ardeleanu, 2020, Clinical pharmacology in drug development.

Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials

C. Bachert, J. Mullol, G. Canonica, 2021, Allergy.

Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies

J. Mullol, C. Hopkins, I. Guillemin, 2022, Allergy.

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

C. Bachert, S. Fujieda, S. Takeno, 2021, Allergy.

Real-World Cost of Nasal Polyps Surgery and Risk of Major Complications in the United States: A Descriptive Retrospective Database Analysis

S. Kamat, Wenzhen Ge, S. Siddiqui, 2022, ClinicoEconomics and outcomes research : CEOR.

Real-World Cost of Nasal Polyps Surgery and Risk of Major Complications in the United States: A Descriptive Retrospective Database Analysis

S. Kamat, Wenzhen Ge, S. Siddiqui, 2022 .

Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis

C. Bachert, C. Hopkins, A. Peters, 2021, The Laryngoscope.

Dupilumab improves health-related quality of life in severe chronic rhinosinusitis with nasal polyps.

J. Mullol, C. Hopkins, I. Guillemin, 2022, Allergy. European Journal of Allergy and Clinical Immunology.